AllerT: Additional Phase IIb data

Additional data from the double-blind, European Phase IIb AN004T trial in 240 patients with moderate to severe birch pollen allergy showed that 50 and 100 µg doses of subcutaneous AllerT each led to a 20-fold increase in allergen-specific IgG4 levels from baseline to 4 weeks after treatment and prior to the 2013 birch pollen season, while IgG4 levels were unchanged for placebo (p<0.0001 for both). Additionally, elevated IgG4 levels were sustained for both doses of AllerT during the 2013 birch pollen season, while IgG4 levels remained unchanged for placebo. Patients received 5 subcutaneous injections of AllerT or placebo over a 2-month period as a pre-seasonal treatment. ...